News & Events about Generation Bio Co.
Latest Ratings for GBIO
DateFirmActionFromTo Dec 2021JMP SecuritiesMaintainsMarket Outperform Dec 2021NeedhamMaintainsBuy Jun 2021JMP SecuritiesInitiates Coverage OnMarket Outperform
View More Analyst Ratings for GBIO
View the Latest Analyst Ratings
read more...
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene ...
Generation Bio (NASDAQ:GBIO Get Rating) had its target price reduced by JMP Securities from $11.00 to $7.00 in a report issued on Thursday morning, The Fly reports. JMP Securities currently has a market outperform rating on the stock. Other equities research analysts have also recently ...
Generation Bio Co. (NASDAQ:GBIO Get Rating) COO Antoinette Paone sold 2,828 shares of the firms stock in a transaction on Thursday, September 29th. The shares were sold at an average price of $5.24, for a total value of $14,818.72. The sale was disclosed in a document filed with the SEC, which is ...
Generation Bio Co. (NASDAQ:GBIO Get Rating) Director Charles A. Rowland, Jr. purchased 18,784 shares of the stock in a transaction that occurred on Tuesday, September 13th. The shares were purchased at an average price of $5.20 per share, for a total transaction of $97,676.80. Following the ...